Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | KDM1A | O60341 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | INSR | P06213 | 1/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.79 |
| ▸ | NQO2 | P16083 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | DRD1 | P21728 | 1/20 | 0.79 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | CCKAR | P32238 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26638151 | 0.97 | EGFR (0.76) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL31486523 | 0.96 | EGFR (0.84) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL31486391 | 0.93 | EGFR (0.80) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL30773419 | 0.92 | EGFR (0.77) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL26637860 | 0.92 | EGFR (0.92) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL26637961 | 0.91 | EGFR (0.80) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19516489 | 0.91 | EGFR (0.80) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336957 | 0.90 | EGFR (0.92) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL17822350 | 0.90 | EGFR (0.80) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL26637717 | 0.89 | EGFR (0.80) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686194-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-15 | — | — | EP | claimed |
| EP-3089741-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291 | ASTRAZENECA AB (SE) | 2021-03-10 | — | — | EP | claimed |
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (DE) | 2025-09-04 | — | — | US | disclosed |
| CN-117715647-A | Treatment of cancer with NK cells and CD38 targeting antibodies | 埃迪瓦生物治疗公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117545490-A | Treatment of cancer with NK cells and HER2 targeting antibodies | 埃迪瓦生物治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023213850-A1 | INHIBITORS OF TAU PROTEINS | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) | 2023-11-09 | — | — | WO | disclosed |
| CN-113855695-B | Colon releasing oral compound medicine composition and its preparing method | 上海理工大学 | 2023-06-06 | — | — | CN | disclosed |
| EP-4119551-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | Astrazeneca AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| CN-112430231-B | Industrial preparation method of AZD9291 | 德州德药制药有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-107522690-B | Preparation method of Osimetinib | 海南先声药业有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-112358468-B | Industrial synthesis method of AZD9291 | 德州德药制药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3686194-B1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-09-15 | — | — | EP | disclosed |
| CN-112430231-A | Industrial preparation method of AZD9291 | 德州德药制药有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-112358468-A | Industrial synthesis method of AZD9291 | 德州德药制药有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-111053780-A | Oxcetitinib pharmaceutical composition and application thereof | 正大天晴药业集团股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-10167275-B2 | AZD9291 intermediate and preparation method therefor | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20180072706-A1 | AZD9291 INTERMEDIATE AND PREPARATION METHOD THEREFOR | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275968-A1 | INHIBITORS OF TAU PROTEINS | MAPT, PSEN2, PSEN1 | EGFR 4305/4885MLNR 4599/4885KDM1A 2780/4885 |
| US-10167275-B2 | AZD9291 intermediate and preparation method therefor | WEE2, WEE1, PIM1 | EGFR 489/4885MLNR 716/4885KDM1A 819/4885 |
| US-20180072706-A1 | AZD9291 INTERMEDIATE AND PREPARATION METHOD THEREFOR | WEE2, WEE1, PIM1 | EGFR 489/4885MLNR 716/4885KDM1A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.